Mark D. Tyson, II, M.D., M.P.H.

Mark D. Tyson II, M.D., is a urologic oncologist, with subspecialty interest in bladder cancer. His clinical focus includes:

• Treatments for muscle invasive and nonmuscle invasive bladder cancer.
• Robotic, open, and single port cystectomy
• Ileal conduits and orthotopic neobladders
• Intravesical therapy for nonmuscle invasive bladder cancer
• Understanding and improving quality of life for patients with bladder cancer
• Blue light cystoscopy, including in-office flexible blue light.

In addition to his clinical activities, Dr. Tyson is active in research and education, providing mentorship to trainees. He authors expert content and publishes regularly in scientific journals. He is currently recruiting patients for multiple clinical trials for patients with bladder cancer:

• SWOG S1602: A phase III randomized trial to evaluate the influence of BCG strain differences and T-cell priming with intradermal BCG before intravesical therapy for BCG-naive high-grade non-muscle invasive bladder cancer.
• TAR-200-103: A multicenter study evaluating safety and efficacy of TAR-200 in subjects with muscle-invasive urothelial carcinoma of the bladder who are ineligible for or refuse cisplatin-based chemotherapy and who are unfit for radical cystectomy.
• UGN-102: A phase IIb, single-arm, multicenter trial to evaluate the efficacy and safety of UGN-102 as a chemoablation agent in patients with low grade non-muscle invasive bladder cancer at intermediate risk of recurrence.
• KEYNOTE-676 Cohort A and Cohort B: A phase III, randomized comparator-controlled clinical trial to study the efficacy and safety of Pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guerin (BCG) in participants with high-risk non-muscle invasive bladder cancer that is either persistent or recurrent following BCG induction (Cohort A) or that is naïve to BCG treatment (Cohort B).
• ALLIANCE A031803: A phase II trial of intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer.
• BOND 003: A phase III study of CG0070 in patients with nonmuscle invasive bladder cancer unresponsive to BCG.
• CISTO: The comparison of intravesical therapy and surgery as treatment options for bladder cancer study.

Dr. Tyson also provides second opinions remotely for newly diagnosed bladder, testis, kidney and prostate cancers.